TL;DR - Kimberly-Clark (KMB) filed for EU merger approval of its $48.7B Kenvue acquisition on August 26; EU provisional deadline is September 29, 2026 - Deal terms: $3.50 cash + 0.14625 KMB shares per KVUE share ($21.01 total at announcement pricing) - US HSR waiting period expired February 2026, granting clearance; EU FSR cleared; China SAMR entered Phase 2 review, adding a potential delay - Combined entity: $32B in annual revenue, $2.1B in run-rate synergies, EPS accretive by Year 2
Part A: The Deal
Kimberly-Clark filed for European Commission merger approval of its Kenvue acquisition on August 26, 2026. The EU's preliminary review has a provisional deadline of September 29. If cleared at that stage, close could still occur in the second half of 2026. If referred to Phase 2, the timeline extends by several months.
Both boards and both shareholder bases have approved the transaction. The US Hart-Scott-Rodino waiting period expired on February 4, 2026, granting antitrust clearance. The EU's Foreign Subsidies Regulation review has already been cleared. The two remaining open items are EU merger control and China's SAMR review.
Deal Terms
| Item | Detail |
|---|---|
| Enterprise Value | ~$48.7 billion |
| Per-share Consideration | $21.01 ($3.50 cash + 0.14625 KMB shares) |
| EBITDA Multiple | 14.3x LTM adjusted EBITDA (8.8x including synergies) |
| Combined Revenue | ~$32 billion (2025 basis) |
| Combined Adj. EBITDA | ~$7 billion |
| Post-close Ownership | KMB shareholders 54%, KVUE shareholders 46% |
| Headquarters | Irving, Texas (KMB maintained) |
| Financing | Cash on hand, new debt (JPMorgan committed), IFP business sale proceeds |
Synergy Summary
| Type | Amount |
|---|---|
| Cost Synergies | $1.9 billion |
| Revenue Synergies (incremental profit) | $500 million |
| Reinvestment Offset | ($300 million) |
| Total Run-Rate Synergies | $2.1 billion |
| One-Time Integration Costs (first two years) | $2.5 billion |
| EPS Accretion Timeline | Expected by Year 2 |
KMB CEO Mike Hsu described Kenvue as "uniquely positioned at the intersection of CPG and healthcare, with exceptional talent and a differentiated brand offering." The combined company would hold 10 billion-dollar brands across consumer health and personal care.
Part B: Three Watch Points for Investors
1. The September 29 EU Deadline Is the Immediate Catalyst
The European Commission has until September 29, 2026, to issue a Phase 1 decision on the deal. Three outcomes are possible:
| Outcome | Impact |
|---|---|
| Phase 1 unconditional clearance | Deal closes H2 2026 on schedule |
| Phase 1 clearance with remedies | Minor divestitures required; close delayed slightly |
| Phase 2 referral | Timeline extends approximately 4–6 months; deal spread widens |
KMB and Kenvue operate in different product segments. KMB leads in tissue and personal care (Kleenex, Huggies, Scott), while Kenvue holds consumer health brands including Tylenol (OTC analgesic), Neutrogena (skin care), Listerine (oral care), and Band-Aid (first aid). Limited direct product overlap historically supports Phase 1 clearance, but the EC may scrutinize distribution and shelf-space dynamics in European markets.
2. China SAMR Phase 2 Is the Wildcard
China's State Administration for Market Regulation has entered a Phase 2 antitrust review. China's AML provides a Phase 2 review of 90 days, extendable by an additional 60 days, within a total statutory clock of 180 days (including the initial 30-day phase). China's SAMR has become more assertive in reviewing large foreign consumer goods deals.
A SAMR hold does not necessarily block the deal but can push close well past the H2 2026 target. Investors should watch for any SAMR timeline announcement or indication of remedies requested.
3. Synergy Credibility and Leverage Profile
The $2.1B synergy target comes with a cost: $2.5B in one-time integration charges over the first two years. The net present value of synergies exceeds integration costs over a multi-year horizon, but the near-term cash drag is real.
KMB is funding the deal with cash, new debt committed by JPMorgan, and proceeds from the sale of its 51% stake in the IFP business. Added leverage increases interest burden at a time when KMB's core tissue business faces input cost pressures.
EPS is expected to be accretive by Year 2. That timeline depends on execution of the cost savings program, the larger bucket at $1.9B.
Deal Arbitrage Context
At announcement, KVUE shares were valued at $21.01 in deal consideration (using KMB's closing price as of October 31, 2025). The current spread between KVUE's market price and implied deal value reflects the market's discount for regulatory risk. An EU Phase 1 clearance on September 29 would compress that spread substantially.
Both KMB and KVUE shareholders overwhelmingly approved the deal, removing shareholder approval risk from the equation.
This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any security. Past performance is not indicative of future results.
Sources: - Kimberly-Clark to Acquire Kenvue — Kenvue IR (Nov 2025) - KMB and KVUE Shareholders Approve — KMB IR - Kimberly-Clark files Kenvue acquisition for EU approval — MLex - Kimberly-Clark secures EU FSR clearance — MLex - KMB Form 10-Q FY2026 (HSR expiry Feb 4, 2026) — SEC EDGAR - China SAMR Phase 2 review — Seeking Alpha - Kimberly-Clark sells 51% IFP stake to Suzano — Manufacturing Dive
